(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square - 2Energy security rifts widen in Europe
- 3Pick Your Favored method of transportation
- 4Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- 5Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
- Germany records first wolf bite on human since repopulation
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- Man threatens attack on German high-speed train, 12 lightly injured
- Portugal among EU countries with the most people working close to 50 hours a week
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- German Easter peace marches draw tens of thousands
- Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
- UK can legally stop shadow fleet tankers, ministers believe
- Israel’s mixed messaging on Christmas draws controversy
